Skip to main content
Passa alla visualizzazione normale.


Pari opportunità

GIUSEPPE CABIBBO

The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma

  • Authors: Lai Quirino, De Matthaeis Nicoletta, Finotti Michele, Galati Giovanni, Marrone Giuseppe, Melandro Fabio, Morisco Filomena, Nicolini Daniele, Pravisani Riccardo, Giannini Edoardo G, Cabibbo Giuseppe
  • Publication year: 2023
  • Type: Review essay (rassegna critica)
  • OA Link: http://hdl.handle.net/10447/653275

Abstract

Aim To evaluate the impact of antiplatelet therapy (APT)on the incidence of hepatocellular carcinoma (HCC) and mortality following its treatment. Methods A systematic literature search was performed using PubMed and Cochrane Central Register of Controlled Trials Databases. Two HCC clinical settings were explored: (i) incidence, and (ii) death after any HCC treatment. Odds ratios (OR) and 95% confidence intervals (95%CI) were calculated to compare the pooled data between patients who received or did not receive APT. Results A total of 20 studies were identified, of whom 15 focused on HCC incidence, including 2,685,009 patients, and five on post-treatment death, including 3281 patients. APT was associated with an overall reduced risk of HCC incidence (OR: 0.63; 95%CI = 0.51-0.79; p < 0.001) as well as of post-treatment mortality (OR: 0.54; 95%CI = 0.35-0.83; p = 0.006). Conclusions Current data suggest that APT correlated with higher HCC incidence and poor overall survival following tumour treatment.